New Medicines of 2015
Onivyde is a prescription drug used in combination with fluorouracil and leucovorin to treat advanced pancreatic cancer. Onivyde belongs to a group of drugs called topoisomerase I inhibitors, which work by stopping the growth of cancer cells. This medication is available as a liquid to be given intravenously (into a vein) by a healthcare professional. Common side effects include diarrhea, fatigue and vomiting. Current treatment options are limited for advanced pancreatic cancer, and one study found that patients treated with Onivyde (in combination with fluorouracil and leucovorin) lived longer.
Reviewed by:
Review Date:
December 29, 2015Citation:
U.S. Food and Drug Administration, "FDA approves first-of-its-kind product for the treatment of melanoma", 2015 U.S. Food and Drug Administration, "FDA approves Praxbind, the first reversal agent for the anticoagulant Pradaxa", 2015 U.S. Food and Drug Administration, "FDA approves Ninlaro, new oral medication to treat multiple myeloma", 2015 U.S. Food and Drug Administration, "FDA approves new treatment for HIV", 2015 U.S. Food and Drug Administration, "FDA approves Nucala to treat severe asthma", 2015 U.S. Food and Drug Administration, "FDA approves new treatment for advanced pancreatic cancer", 2015 U.S. Food and Drug Administration, "FDA approves first treatment for sexual desire disorder", 2015 U.S. Food and Drug Administration, "FDA approves new drug to treat heart failure", 2015 U.S. Food and Drug Administration, "FDA approves Praluent to treat certain patients with high cholesterol", 2015 U.S. Food and Drug Administration, "FDA approves Corlanor to treat heart failure", 2015 All images appear courtesy of Dreamstime
Last Updated:
December 29, 2015